Many pediatric and adolescent patients who received second-generation antipsychotic medications experienced significant weight gain, along with varied adverse effects on cholesterol and triglyceride levels and other metabolic measures.
Treatment for psychotic disorders, bipolar disorder, and nonpsychotic mental disorders for children and adolescents in the United States often includes second-generation antipsychotic medications.
Increasingly, the cardiometabolic effects of second-generation antipsychotic medications have raised concern. Cardiometabolic adverse effects, such as age-inappropriate weight gain, obesity, hypertension, and lipid and glucose abnormalities, are particularly problematic during development because they predict adult obesity, the metabolic syndrome, cardiovascular morbidity, and malignancy. The cardiometabolic effects of these medications have not been sufficiently studied in children and adolescent patients who have not previously received them.
Christoph U Correll, of Zucker Hillside Hospital, North Shore-Long Island Jewish Health System, Glen Oaks, New York, and colleagues conducted a study of weight and metabolic changes in a group of 272 pediatric patients ( ages 4 to 19 years ) who had not previously received antipsychotic medication. Patients had mood spectrum ( 47.8 percent ), schizophrenia spectrum ( 30.1 percent ), and disruptive or aggressive behavior spectrum ( 22.1 percent ) disorders. Fifteen patients who refused participation or were nonadherent to medications served as a comparison group. Patients were treated with the antipsychotic medications Aripiprazole ( Abilify ), Olanzapine ( Zyprexa ), Quetiapine ( Seroquel ), or Risperidone ( Risperdal ) for 12 weeks.
After a median of 10.8 weeks of treatment, weight increased by an average of 18.7 lbs with Olanzapine ( n = 45 ), by 13.4 lbs with Quetiapine ( n = 36 ), by 11.7 lbs with Risperidone ( n = 135 ), and by 9.7 lbs with Aripiprazole ( n = 41 ) compared with minimal weight change of 0.4 lbs in the untreated comparison group ( n = 15) .
Each antipsychotic medication was associated with significantly increased fat mass and waist circumference. Altogether, 10 percent to 36 percent of patients transitioned to overweight or obese status within 11 weeks.
The researchers also found that adverse changes during the study period reached statistical significance for Olanzapine and Quetiapine for total cholesterol, triglycerides, non-HDL cholesterol, and ratio of triglycerides to HDL cholesterol.
With Risperidone, levels of triglycerides increased significantly. Metabolic baseline-to-end-point changes were not significant with Aripiprazole or in the untreated comparison group. Patients receiving Quetiapine had modestly higher incidence rates of hyperglycemia and the metabolic syndrome and patients receiving Olanzapine experienced the highest incidence rates.
According to Authors, the results, together with data from first-episode studies, suggest that guidelines for antipsychotic medication exposure for vulnerable pediatric and adolescent patients naive to antipsychotic medication should consider more frequent ( e.g., biannual ) cardiometabolic monitoring after the first 3 months of treatment. Finally, in view of poor physical health outcomes and suboptimal metabolic monitoring in the severely mentally ill, the benefits of second-generation antipsychotic medications must be balanced against their cardiometabolic risks through a careful assessment of the indications for their use, consideration of lower-risk alternatives, and proactive adverse effect monitoring and management.
Source: JAMA, 2009
Link: Xapedia - Medical Encyclopedia